Enanta Pharmaceuticals, Inc.

Samuel Bartlett

Yat Sun Or

Joseph D Panarese

Dexter Davis

Nathaniel Thomas Kenton

Katherine Chong

Guoqiang Wang

Sean M Rafferty

Xiaowen Peng

Ruichao Shen

Xuechao Xing

Hui Cao

Yong He

Wei Li

Jiajun Zhang

Sean Rafferty

Matthew C Rhodes

Jonathan Thielman

The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, thereof: which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.

Spiropyrrolidine derived antiviral agents

The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, thereof: which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

Functionalized heterocycles as antiviral agents

Heterocyclic antiviral agents

Saturated spirocyclics as antiviral agents

Alkyne-containing antiviral agents

Functionalized heterocyclic compounds as antiviral agents

The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts thereof: which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

Substituted heterocycles as antiviral agents

The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, thereof: which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable slat thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.

Functionalized peptides as antiviral agents

Growing community of inventors

Brighton, MA, United States of America

Samuel Bartlett